focus -WSS

focus

author：knowledge 2025-09-30 08:53:32 - browse：4

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Rise in cancer among younger people worries and puzzles doctors

WSS

Crinetics acromegaly drug succeeds in late

The battle over 'scope creep' and who gets to be called 'doctor'

'Investigate these claims': UFO transparency at center of House hearing

Crinetics acromegaly drug succeeds in late

Rise in cancer among younger people worries and puzzles doctors

Illumina names Agilent executive as new CEO

explore

focus

focus

Walensky prepares to leave CDC — and Congress — behind

Democrats decry new health bill for going easy on private equity

Apple is now the first public company to be valued at $3 trillion

Search called off for baby washed away in Pennsylvania flash flood

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Roche’s Alnylam deal shows drug firms interested in heart drugs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

'Make People Better': The CRISPR babies story you probably don't know

Activists slam private health insurers over coverage restrictions

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

leisure time

Listen: Biogen's potential pivot, & Illumina's next chapter

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

'Investigate these claims': UFO transparency at center of House hearing

Ethical issues complicate the benefits of medical crowdfunding

Will the FTC rein in IQVIA's health data empire?

Ethical issues complicate the benefits of medical crowdfunding

focus

hotspot

explore

focus